[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP0671951A1 - Anticorps humanises reagissant avec l-selectine - Google Patents

Anticorps humanises reagissant avec l-selectine

Info

Publication number
EP0671951A1
EP0671951A1 EP94903357A EP94903357A EP0671951A1 EP 0671951 A1 EP0671951 A1 EP 0671951A1 EP 94903357 A EP94903357 A EP 94903357A EP 94903357 A EP94903357 A EP 94903357A EP 0671951 A1 EP0671951 A1 EP 0671951A1
Authority
EP
European Patent Office
Prior art keywords
immunoglobulin
humanized
human
light chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94903357A
Other languages
German (de)
English (en)
Other versions
EP0671951A4 (fr
Inventor
Man Sung Co
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of EP0671951A1 publication Critical patent/EP0671951A1/fr
Publication of EP0671951A4 publication Critical patent/EP0671951A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates generally to the combination of recombinant DNA and monoclonal antibody technologies for developing novel biologies and, more particularly, for example, to the production of non- immunogenic (in humans) immunoglobulins specific for the L- selectin protein and their uses in vitro and in vivo .
  • adhesion molecules generally glycoproteins, expressed on cell membranes. Often, an adhesion molecule on one cell type will bind to another adhesion molecule expressed on a different cell type, forming a receptor counter-receptor pair.
  • adhesion molecules Three very important classes of adhesion molecules are the integrins, selectins, and immunoglobulin (Ig) superfamily members (see Springer, Nature 346:425 (1990); Osborn, Cell 62:3 (1990); Hynes, Cell 69:11 (1992), all of which are incorporated herein by reference in their entirety for all purposes).
  • Integrins are heterodimeric transmembrane glycoproteins consisting of an ⁇ chain (120-180 kD) and a ⁇ chain (90-110 kD) , generally having short cytoplasmic domains.
  • the ⁇ subunits all share sequence homology and motifs with each other, as do the ⁇ subunits.
  • the three known integrins containing the ⁇ subunit designated ⁇ 2 are important to the function of T cells, neutrophils and monocytes.
  • LFA-1 (_ L jS 2 ) is widely distributed on lymphocytes, granulocytes and monocytes.
  • ICAM-1 Its counter-receptor is ICAM-1 (and perhaps of lesser importance, ICAM-2) an Ig family molecule which is expressed on many cells including leukocytes and is up-regulated on vascular endothelium by cytokines such as TNF and IL-1. Blocking LFA-1 on T cells with antibodies to either the ⁇ or ⁇ subunit strongly inhibits adhesion-dependent functions such as CTL-mediated lysis of target cells.
  • Mac-1 (_- M/ S 2 ) is distributed on neutrophils and monocytes, and its counter-receptor is also ICAM-1 (and possibly ICAM-2) .
  • Mac-1 is the type 3 complement receptor (CR3) and binds the C3bi fragment.
  • the third ⁇ 2 integrin, P150,95 ( ⁇ x /3 2 ) , is also found on neutrophils and monocytes, but seems of less importance.
  • the ⁇ subunits of LFA-1, Mac-1 and P150,95 are also given the respective CD designations CDlla, CDllb and CDllc, while ⁇ 2 is also denoted CD18, so that LFA-1 is CDlla/CD18 and Mac-1 is CDllb/CD18.
  • L- selectin also called LECAM-1, Mel-14 or LAM-1
  • E-selectin also called ELAM-1
  • P-selectin also called GMP140 or PADGEM
  • L-selectin has a dual role: it is a homing receptor on T cells for the high endothelial venules of peripheral lymph nodes, and it is an adhesion molecule on neutrophils for endothelium (Hallmann et al., Biochem . Biophys . Res .
  • E-selectin and P-selectin are both induced on endothelium by cytokines, although with different kinetics.
  • L-selectin is a counter- receptor on neutrophils for both E-selectin and P-selectin (Picker et al., Cell 66:921 (1991), which is incorporated herein by reference in its entirety for all purposes) , although all three selectins probably have other counter- receptors as well.
  • E-selectin binds the carbohydrate group sialyl Lewis x (sLex) (Lowe et al., Cell 63:475 (1990)), which is incorporated herein by reference in its entirety for all purposes) , and while this carbohydrate is prominently presented on L-selectin (Picker et al., Cell 66:921 (1991)), it may occur on other proteins as well.
  • E- selectin is expressed especially in cutaneous sites of inflammation and also serves as an adhesion molecule for skin-homing T cells that may contribute to the inflammation (Picker et al., Nature 349:796 (1991), which is incorporated herein by reference in its entirety for all purposes) .
  • antibodies to CDlla, CDllb, CD18, L-selectin and E-selectin all block binding of neutrophils to activated endothelial cells to a lessor or greater degree, but the most complete inhibition is generally achieved by the combination of an antibody to CD18 and an antibody to L- or E-selectin (see, e . g. , Luscinskas, J “ . Immunol . 142:2257 (1989)), which is incorporated herein by reference in its entirety for all purposes) .
  • a recent but now widely accepted model accounts for these facts with a three step process of adhesion (Butcher, Cell 67:1033 (1991), which is incorporated herein by reference in its entirety for all purposes) .
  • neutrophils reversibly bind to inflamed vascular endothelium via the selectins, which bind well under conditions of flow, causing the neutrophils literally to roll along the vascular wall.
  • the neutrophils are then activated by a variety of stimulants surrounding or released by the endothelium, including IL-8, PAF and C5a.
  • the activated neutrophils shed L-selectin and up-regulate Mac-l.
  • ICAM-1 and perhaps other counter-receptors on the endothelial cells allows stable adhesion and extravasation through the endothelium.
  • antibodies or other antagonists of the integrin and selectin adhesion molecules could abort this process, by preventing neutrophils from binding to endothelium and from extravasating into tissues. v Hence such antibodies could be used to treat a great many different disease conditions of which inflammation is an important component.
  • anti-CD18 antibodies which bind to both LFA-1 and Mac-1, have been useful in reducing ischemia-reperfusion injury (see, e . g. , Vedder et al., J . Clin . Invest . 81:939 (1988); Vedder et al., Proc. Natl . Acad . Sci . USA 87:2643 (1990); U.S. Patent No. 4,797,277). They also reduce neutrophil-mediated damage in the lung in response to various insults (Doerschuk et al., J. Immunol . 144:2327 (1990) and Mulligan et al., J. Immunol .
  • anti-CD18 antibodies also protect from lethality due to meningitis (Tuomanen et al., J. Exp . Med . 170:959 (1990)). They may also be useful in ' preventing or treating organ transplant rejection because they block T-cell function.
  • an anti-E-selectin antibody greatly reduced vascular injury induced by immune complex deposition in the skin or lungs of rats, and substantially reduced neutrophil accumulation at those sites (Mulligen et al., J. Clin . Invest . 88:1396 (1991)). Also, in a primate model of extrinsic asthma, an anti-E-selectin antibody greatly reduced neutrophil influx into the lung and associated late-phase airway obstruction after antigen inhalation (Gundel et al., J. Clin . Invest . 88:1407 (1991)).
  • mice DREG-55, mouse DREG-56 and mouse DREG-200 have been developed that bind to human L-selectin (Kishimoto et al., Proc. Natl . Acad . Sci . USA 87:2244 (1990), which is incorporated herein by reference in its entirety for all purposes) .
  • These antibodies partially or completely block the binding of human lymphocytes to peripheral lymph node high endothelial venules, and the binding of human neutrophils to stimulated human umbilical vein endothelial cells (Kishimoto et al., Blood 78:805 (1991), which is incorporated herein by reference in its entirety for all purposes) .
  • the capacity of these antibodies to block binding of neutrophils to endothelial cells indicates that the antigen to which they bind, L-selectin, may be an appropriate target for potential therapeutic agents.
  • mouse monoclonal antibodies such as mouse DREG-200 have certain drawbacks in human treatment, particularly in repeated therapeutic regimens as explained below.
  • Mouse monoclonal antibodies for example, have a relatively short circulating half-life, and lack other important immunoglobulin functional characteristics when used in humans.
  • non-human monoclonal antibodies contain substantial stretches of amino acid sequences that will be immunogenic when injected into a human patient. Numerous studies have shown that, after injection of a foreign antibody, the immune response elicited by a patient against an antibody can be quite strong, essentially eliminating the antibody's therapeutic utility after an initial treatment. Moreover, as increasing numbers of different mouse or other antigenic (to humans) monoclonal antibodies can be expected to be developed to treat various diseases, after the first or several treatments with any different non-human antibodies, subsequent treatments even for unrelated therapies can be ineffective or even dangerous in themselves, because of cross-reactivity. While the production of so-called "chimeric antibodies" (e .g. , mouse variable regions joined to human constant regions) has proven somewhat successful, a significant immunogenicity problem remains.
  • chimeric antibodies e .g. , mouse variable regions joined to human constant regions
  • the present invention provides novel compositions useful, for example, in the treatment of inflammatory human disorders, the compositions containing humanized immunoglobulins specifically capable of binding to L- selectin.
  • the immunoglobulins can have two pairs of light chain/heavy chain complexes, at least one chain comprising one or more mouse complementarity determining regions functionally joined to human framework region segments.
  • mouse complementarity determining regions with or without additional naturally-associated mouse amino acid residues, can be introduced into human framework regions to produce humanized immunoglobulins capable of binding to the L-selectin at affinity levels stronger than about 10 7 M "1 .
  • These humanized immunoglobulins will also be capable of blocking the binding of the CDR-donating mouse monoclonal antibody to L-selectin.
  • the immunoglobulins, including binding fragments and other derivatives thereof, of the present invention may be produced readily by a variety of recombinant DNA techniques, with ultimate expression in transfected cells, preferably immortalized eukaryotic cells, such as myeloma or hybridoma cells.
  • Polynucleotides comprising a first sequence coding for humanized immunoglobulin framework regions and a second sequence set coding for the desired immunoglobulin complementarity determining regions can be produced synthetically or by combining appropriate cDNA and genomic DNA segments.
  • the humanized immunoglobulins may be utilized alone in substantially pure form, or together with a chemotherapeutic agent such as a non-steroidal anti- inflammatory drug (e.g., aspirin), a corticosteroid, or an immunosuppressant. All of these compounds will be particularly useful in treating inflammatory disorders.
  • a chemotherapeutic agent such as a non-steroidal anti- inflammatory drug (e.g., aspirin), a corticosteroid, or an immunosuppressant. All of these compounds will be particularly useful in treating inflammatory disorders.
  • the humanized immunoglobulins or their complexes can be prepared in a pharmaceutically acceptable dosage form, which will vary depending on the mode of administration.
  • FIGURES Figure 1 Sequences of the CDNA and translated amino acid sequences of the light chain (A) and heavy chain (B) variable regions of the mouse DREG-200 antibody.
  • the mature heavy chain begins with amino acid 20 E, and the mature light chain begins with amino acid 21 D, preceded by the respective signal sequences.
  • FIG. 1 Amino acid sequences of the mature light chain (A) and heavy chain (B) variable regions of the mouse DREG-200 antibody (upper lines) and humanized DREG-200 antibody (lower lines) .
  • the three CDRs in each chain are underlined.
  • Residues in the framework that have been replaced with mouse amino acids or typical human amino acids in the humanized antibody are double underlined.
  • Figure 3 Nucleotide sequences of the genes encoding the light chain (A) and heavy chain (B) variable regions of the humanized DREG-200 antibody, beginning and ending with the Xbal sites, and translated amino acid sequences, including signal sequences.
  • FIG. 4 Competitive binding of mouse and humanized IgGl and lgG4 DREG-200 antibodies.
  • the target cells were L2-1 cells, a mouse pre-B cell line, that was transfected with a human L-selectin gene and thus expresses human L-selectin (Berg et al., Biochem . Biophys . Res . Comm . 184:1048 (1992)).
  • 5 x 10 5 cells were incubated with 3 ng of 125 I-labeled tracer mouse antibody (2 ⁇ Ci/ ⁇ g) , together with increasing amounts of mouse or humanized competitor antibody as indicated in 0.2 ml of binding buffer (PBS + 2% FBS + 0.1% azide) for 1 hr at 4°C.
  • FIG. 1 Binding of human neutrophils to IL-1 stimulated human umbilical cord endothelial cells (HUVEC) .
  • the neutrophils were first treated with irrelevant control antibody, mouse DREG-200 antibody, or humanized IgGl DREG-200 antibody, or left untreated, as indicated.
  • the Figure shows for cats treated with humanized DREG-200 or control antibody, from left to right: area at risk/total ventricular area; necrotic tissue area/area at risk; and necrotic tissue area/total left ventricle area. Brackets represent +/- SEM for six cats; heights of bars are means.
  • substantially identical or “substantial homology” means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 65 percent sequence identity, preferably at least 80 or 90 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g., 99 percent sequence identity).
  • residue positions which are not identical differ by conservative amino acid substitutions.
  • amino acids are grouped as follows: Group I (hydrophobic sidechains) : norleucine, met, ala, val, leu, ile; Group II (neutral hydrophilic side chains) : cys, ser, thr; Group III (acidic side chains) : asp, glu; Group IV (basic side chains) : asn, gin, his, lys, arg; Group V (residues influencing chain orientation) : gly f pro; and Group VI (aromatic side chains) : trp, tyr, phe. Conservative .substitutions involve substitutions between amino acids in the same class. Non- conservative substitutions constitute exchanging a member of one of these classes for a member of another.
  • Amino acids from the variable regions of the mature heavy and light chains of immunoglobulins are designated Hx and Lx respectively, where x is a number designating the position of an amino acids according to the scheme of Kabat, Seguences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD, 1987 and 1991) .
  • Kabat lists many amino acid sequences for antibodies for each subclass, and lists the most commonly occurring amino acid for each residue position in that subclass.
  • Kabat uses a method for assigning a residue number to each amino acid in a listed sequence, and this method for assigning residue numbers has become standard in the field.
  • Rabat's scheme is extendible to other antibodies not included in his compendium by aligning the antibody in question with one of the consensus sequences in Kabat.
  • the use of the Kabat numbering system readily identifies amino acids at equivalent positions in different antibodies. For example, an amino acid at the L50 position of a human antibody occupies the equivalent position to an amino acid position L50 of a mouse antibody
  • both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2,> FR3, CDR3 and FR4.
  • the assignment of amino acids to each domain is in accordance with the definitions of Kabat (1987) and (1991) , supra , or Chothia & Lesk, J . Mol . Biol . 196:901-917 (1987); Chothia et al., Nature 342:878-883 (1989).
  • humanize immunoglobulins specifically reactive with L-selectin related epitopes are provided. These immunoglobulins usually have binding affinities to L-selectin of at least about 10 7 M "1 , and preferably 10 8 M” 1 to 10 9 M "1 , 10 10 M” 1 or stronger and, are capable of, e . g. , binding to neutrophils.
  • the humanized immunoglobulins will have a human framework and will have one or more complementarity determining regions (CDRs) from an immunoglobulin, typically a mouse immunoglobulin, specifically reactive with L-selectin.
  • CDRs complementarity determining regions
  • one or more of the CDRs will come from the mouse DREG-200 antibody, and the humanized immunoglobulin will be of the IgGl or IgG4 isotype.
  • the immunoglobulins of the present invention which can be produced economically in large quantities, find use, for example, in the treatment of inflammatory disorders in human patients by a variety of techniques.
  • the basic antibody structural unit is known to comprise a tetra er.
  • Each tetramer is composed of two iden ⁇ tical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD) .
  • the NH 2 -terminus of each chain begins a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
  • the COOH part of each chain defines a constant region primarily responsible for effector function.
  • Light chains are classified as either kappa or lambda.
  • Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively.
  • the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids.
  • variable regions of each light/heavy chain pair form the antibody binding site.
  • the chains all exhibit the same general structure of relatively conserved framework regions joined by three hypervariable regions, also called Complementarity Determining Regions or CDRs (see “Sequences of Proteins of Immunological Interest,” Kabat, E. , et al., U.S. Department of Health and Human Services (1987); and
  • immunoglobulin refers to a protein consisting of one or more polypeptides > substantially encoded by immunoglobulin genes.
  • the recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes.
  • the immunoglobulins may exist in a variety of forms besides antibodies; including, for example, Fv, Fab, and (Fab') 2 as well as bifunctional antibodies (e . g. , Lanzavecchia et al., Eur. J . Immunol . 17:105 (1987)) and in single chains (e . g.
  • Chimeric antibodies are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin gene segments belonging to different species.
  • the variable (V) segments of the genes from a mouse monoclonal antibody may be joined to human constant (C) segments, such as 1 and 4 .
  • a typical therapeutic chimeric antibody is thus a hybrid protein consisting of the V or antigen-binding domain from a mouse antibody and the C or effector domain from a human antibody, although other mammalian species may be used.
  • framework region refers to those portions of immunoglobulin light and heavy chain variable regions that are relatively conserved (i .e . , other than the CDRs) among different immunoglobulins in a single species, as defined by Kabat, et al., supra .
  • a "human framework region” is a framework region that is substantially identical (about 85% or more) to the framework region of a naturally occurring human antibody or a consensus sequence of several such antibodies.
  • humanized immunoglobulin refers to an immunoglobulin comprising a human framework, at least one CDR from a non-human antibody, and in which any constant region present is substantially identical to a human immunoglobulin constant region, i . e . , at least about 85-90%, preferably at least 95% identical.
  • all parts of a humanized immunoglobulin, except possibly the CDRs are substantially identical to corresponding parts of one or more native human immunoglobulin sequences.
  • a humanized immunoglobulin would not encompass a chimeric mouse variable region/human constant region antibody.
  • Humanized antibodies have at least three potential advantages over mouse, and in some cases chimeric antibodies, for use in human therapy:
  • the effector portion is human, it may interact better with the other parts of the human immune system (e . g. , destroy the target cells more efficiently by complement-dependen cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC) ) .
  • CDC complement-dependen cytotoxicity
  • ADCC antibody-dependent cellular cytotoxicity
  • the human immune system should not recognize the framework or C region of the humanized antibody as foreign, and therefore the antibody response against such an injected antibody should be less than against a totall foreign mouse antibody or a partially foreign chimeric antibody.
  • 3) Injected mouse antibodies have been reported to have a half-life in the human circulation much shorter than the half-life of normal antibodies (Shaw, D. et al., J. Immunol . 138:4534-4538 (1987)). Injected humanized antibodies will presumably have a half-life more like that of naturally occurring human antibodies, allowing smaller and less frequen doses to be given.
  • the present invention is directed t recombinant DNA segments encoding the heavy and/or light chain CDRs from an immunoglobulin capable of binding to a desired epitope of L-selectin, such as monoclonal antibodies mouse DREG-200, mouse DREG-55 or mouse DREG-56 (Kishimoto et al. (1990), supra , which is incorporated herein by reference in its entirety for all purposes) .
  • the DNA segments encoding these regions will typically be joined to DNA segments encoding appropriate human framework regions. Exemplary DNA sequences, which on expression code for the polypeptide chains comprising the heavy and light chain CDRs of monoclonal antibody mouse DREG-200 are included in Fig. 1.
  • the DNA segments will typically further include an expression control DNA sequence operably linked to the humanized immunoglobulin coding sequences, including naturally-associated or heterologous promoter regions.
  • the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and, as desired, the collection and purification of the light chains, heavy chains, light/heavy chain dimers or intact antibodies, binding fragments or other immunoglobulin forms may follow.
  • nucleic acid sequences of the present invention capable of ultimately expressing the desired humanized antibodies can be- formed from a variety of different polynucleotides (genomic or cDNA, RNA, synthetic oligonucleotides, etc.) and components (e . g. , V, J, D, and C regions), as well as by a variety of different techniques. Joining appropriate genomic and synthetic sequences is presently the most common method of production, but cDNA sequences may also be utilized (see European Patent Publication No. 0239400 and Riechmann, L. et al., Nature 332:323-327 (1988), both of which are incorporated herein by reference in their entirety for all purposes) .
  • Human constant region DNA sequences can be isolated in accordance with well known procedures from a variety of human cells, but preferably immortalized B-cells (see Kabat, supra , and WP87/02671) .
  • the CDRs for producing the immunoglobulins of the present invention will be similarly derived from monoclonal antibodies capable of binding to L- selectin and produced in any convenient mammalian source, including, mice, rats, rabbits, or other vertebrate capable of producing antibodies by well known methods.
  • Suitable source cells for the DNA sequences and host cells for immunoglobulin expression and secretion can be obtained from a number of sources, such as the American Type Culture
  • the CDRs have sequences corresponding to the CDR sequences of mouse DREG-200, mouse DREG-55, or mouse DREG-56, respectively, and may include degenerate nucleotide sequences encoding the corresponding CDR amino acid sequence(s) of mouse DREG-200, mouse DREG-55, or mouse DREG-56.
  • humanized immunoglobulins specifically described herein other "substantially homologous" modified immunoglobulins can be readily designed and manufactured utilizing various recombinant DNA techniques well known to those skilled in the art.
  • Other human antibodies than the Eu antibody discussed in Example 2 can be used as a source of framework sequence. These framework sequences should exhibit a high degree of sequence identity with the mouse DREG-200 variable framework domains from which the CDRs were derived.
  • the heavy and light chain variable framework regions can be derived from the same or different human antibody sequences. Indeed, the heavy and light chain framework regions can each be derived from more than one human antibody.
  • the human antibody sequences can, be the sequences of naturally occurring human antibodies or can be consensus sequences of several human antibodies. See Carter et al., WO 92/22653 (1992).
  • the unnatural juxtaposition of murine CDR regions with human variable framework region can result in unnatural conformational restraints, which, unless corrected by substitution of certain amino acid residues, lead to loss of binding affinity.
  • the selection of amino acid residues for substitution is determined, in part, by computer modelling.
  • Computer hardware and software for producing three- dimensional images of immunoglobulin molecules are widely available.
  • molecular models are produced starting from solved structures for immunoglobulin chains or domains thereof.
  • the chains to be modelled are compared for amino acid sequence similarity with chains or domains of solved three dimensional structures, and the chains or domains showing the greatest sequence similarity is/are selected as starting points for construction of the molecular model.
  • Example 2 discusses in more detail the steps taken to produce a three dimensional computer model for the variable regions of the mouse DREG-200 antibody. This model can in turn serve as a starting point for predicting the three-dimensional structure of an antibody containing the mouse DREG-200 complementarity determining regions substituted in human framework structures. Additional models can be constructed representing the structure when further amino acid substitutions, to be discussed infra , are introduced.
  • substitution of human amino acid residues with murine should be minimized, because > introduction of murine residues increases the risk of the antibody eliciting a HAMA response in humans.
  • Amino acids are selected for substitution based on their possible influence on CDR conformation and/or binding to antigen. Investigation of such possible influences is by modelling, examination of the characteristics of the amino acids at particular locations, or empirical observation of the effects of substitution or mutagenesis of particular amino acids.
  • the human framework amino acid should usually be substituted by the equivalent mouse amino acid if it is reasonably expected that the amino acid:
  • the humanized antibodies of the present invention will usually contain a substitution with a mouse light chain framework residue with a corresponding mouse DREG-200 residue in at least 1, 2, 3, 4 and more usually 5, of the following positions: L87, L54, L66, L76 and L93.
  • the humanized antibodies also usually contain a substitution with a mouse heavy chain framework residue in at least 1 , 2 , 5 , 7 , 9 , 10, 11 and, more usually 12 of the following positions: H93, H95, H98, Hill, H112, H115, H30, H98, Hill, H27, H48, and H72.
  • the human heavy chain acceptor immunoglobulin is Eu
  • the heavy chain also contains a substitution at H113. This position is usually substituted with the amino acid from the equivalent position of a human immunoglobulin having a more typical amino acid residues.
  • CDR regions in humanized antibodies are substantially identical, and more usually, identical to the corresponding CDR regions in the mouse DREG-200 antibody.
  • the framework regions of humanized immunoglobulins are usually substantially identical, and more usually, identical to the framework regions of the human antibodies from which they were derived.
  • the framework regions can vary from the native sequences at the primary structure level by several amino acid substitutions, terminal and intermediate additions and deletions, and the like.
  • Stereoisomers e . g. , D-amino acids
  • unnatural amino acids such as ⁇ ,__-disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present invention.
  • polypeptide fragments comprising only a portion of the primary antibody structure may be produced, which fragments possess one or more immunoglobulin activities (e . g. , binding activity).
  • immunoglobulin activities e . g. , binding activity
  • These polypeptide fragments may be produced by proteolytic cleavage of intact antibodies by methods well known in the art, or by inserting stop codons at the desired locations in the vectors pVk and pVgl-dhfr using site-directed mutagenesis, such as after CHI to produce Fab fragments or after the hinge region to produce (Fab 1 ) 2 fragments.
  • Single chain antibodies may be produced by joining VL and VH with a DNA linker (see Huston et al., supra , and Bird et al., supra) .
  • Fv or Fab fragments may be produced in E. coli according to the methods of Buchner and Rudolph, Bio /Technology 9:157-162 (1991) and Skerra et al., Bio /Technology 9:273-277 (1991), incorporated herein by reference in their entirety for all purposes.
  • Fv and Fab may also be produced by expression of encoding polynucleotides in eukaryotic, preferably mammalian, cells.
  • the immunoglobulin-related genes contain separate functional regions, each having one or more distinct biological activities, the genes may be fused to functional regions from other genes (e .g. , enzymes, see commonly assigned U.S.S.N. 132,387, filed Dec. 15, 1987, which is incorporated herein by reference in its entirety for all purposes) to produce fusion proteins (e . g. , immunotoxins) having novel properties.
  • humanized immunoglobulin sequences in bacterial hosts may be used to advantage to select higher affinity humanized immunoglobulin sequences by mutagenizing the CDR regions and producing bacteriophage display libraries which may be screened for humanized immunoglobulin CDR variants which possess high affinity and/or high specificity binding to L-selectin.
  • One potential advantage of such ' affinity sharpening is the generation of humanized immunoglobulin CDR variants which have improved binding affinity and/or reduced cross-reactivity with molecules other than L-selectins.
  • the DNA sequences will be expressed in hosts after the sequences have been operably linked to (i.e., positioned to ensure the functioning of) an expression control sequence.
  • These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA.
  • expression vectors will contain selection markers, e . g. , tetracycline-resistance (tet R ) , G418-resistance (neo R ) , mycophenolic acid-resistance (gpt) , or HSV-tk, to permit detection of those cells transformed with the desired DNA sequences (see, e .g. , U.S. Patent 4,704,362, which is incorporated herein by reference in its entirety for all purposes) .
  • E. coli is one prokaryotic host useful particularly for cloning the DNA sequences of the present invention.
  • microbial hosts suitable for use include bacilli, such as Bacillus ⁇ ubtili ⁇ , and other enterobacteriaceae, such as Salmonella , Serratia , and various Pseudomonas species.
  • prokaryotic hosts one can also make expression vectors, which will typically contain expression control sequences compatible with the host cell (e . g. , an origin of replication) .
  • expression control sequences compatible with the host cell (e . g. , an origin of replication) .
  • any number of a variety of well- known promoters will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda.
  • the promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation.
  • Saccharomyces is a preferred host, with suitable vectors having expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired.
  • Plants and plant cell cultures may be used for expression of the humanized immunoglobulins of the invention.
  • Preferable plant hosts include, for example: Arabidop ⁇ is , Nicotiana tabacum , Nicotiana ru ⁇ tica , and Solanum tubero ⁇ um.
  • a preferred expression cassette for expressing polynucleotide sequences encoding the humanized anti-L-selectin antibodies of the invention is the plasmid pMOGl ⁇ in which the inserted polynucleotide sequence encoding the humanized immunoglobulin chain is operably linked to a CaMV 35S promoter with a duplicated enhancer; pMOG18 is used according to the method of Sijmons et al., Bio /Technology 8:217-221 (1990), incorporated herein by reference in its entirety for all purposes.
  • pMOG18 is used according to the method of Sijmons et al., Bio /Technology 8:217-221 (1990), incorporated herein by reference in its entirety for all purposes.
  • a preferred embodiment for the expression of humanized immunoglobulins in plants follows the methods of Hiatt et al.
  • Agrobacterium tumifacien ⁇ T-DNA-based vectors may also be used for expressing humanized immunoglobulin sequences, preferably such vectors include a marker gene encoding spectinomycin- resistance or other selectable marker.
  • Insect cell culture may also be used to produce the humanized immunoglobulins of the invention, typically using a baculovirus-based expression system.
  • the humanized immunoglobulins may be produced by expressing polynucleotide sequences encoding the humanized immunoglobulins according to the methods of Putlitz et al.. Bio /Technology 8:651-654 (1990) , incorporated herein by reference in its entirety for all purposes.
  • the method of Putlitz et al. can be followed with the modification that polynucleotide sequences encoding the humanized anti-L-selectin antibodies of the invention are inserted in place of the mouse monoclonal Ab 6A4 heavy chain and light chain cDNA sequences of Putlitz et al.
  • mammalian tissue cell culture may also be used to express and produce the polypeptides of the present invention (see Winnacker, From Gene ⁇ to Clone ⁇ (VCH Publishers, NY, 1987) , which is incorporated herein by reference in its entirety for all purposes) .
  • Mammalian cells are actually preferred, because a number of suitable host cell lines capable of secreting intact immunoglobulins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, preferably myeloma cell lines, etc, or transformed B- cells or hybridomas.
  • Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer (Queen et al., Immunol . Rev. 89:49-68 (1986), which is incorporated herein by reference in its entirety for all purposes) , and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences.
  • Preferred expression control sequences are promoters derived from immunoglobulin genes, SV40, Adenovirus, Bovine Papilloma Virus, cytomegalovirus and the like.
  • a selectable marker such as a neo R expression cassette, is included in the expression vector.
  • Transgenes encoding a humanized immunoglobulin of the invention may be used to generate transgenic nonhuman animals which express the desired humanized immunoglobulin, typically in a recoverable body fluid such as milk or serum.
  • Such transgenes comprise a polynucleotide sequence encoding the humanized immunoglobulin(s) operably linked to a promoter, usually with a linked enhancer, such as a rodent immunoglobulin enhancer or a casein gene promoter/enhancer (Buhler et al.. Bio /Technology 8:140-143 (1990); Meade et al., Bio /Technology 8:443-446 (1990), incorporated herein by reference in its entirety for all purposes) .
  • a linked enhancer such as a rodent immunoglobulin enhancer or a casein gene promoter/enhancer
  • Transgenes may be transferred into cells and embryos according to the methods described in the art and, infra , for homologous recombination constructs.
  • Preferred nonhuman animals include: mice, rats, sheep, cows, and goats; with expression in bovine milk being particularly preferred. See WO91/08216 (1991) (which is incorporated in its entirety for all purposes) . Purification of the humanized antibodies is accomplished by art-known purification methods for immunoglobulin purification.
  • the vectors containing the DNA segments of interest can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment, lipofection, biolistics, viral-based transduction, or electroporation may be used for other cellular hosts. Tungsten particle ballistic transgenesis is preferred for plant cells and tissues. (See, generally, Maniatis et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Press, 1982), which is incorporated herein by reference in its entirety for all purposes.)
  • the whole antibodies, their dimers, individual light and heavy chains, or other immunoglobulin forms of the present invention can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography , gel electrophoresis and the like (see, generally, Scopes, R. , Protein Purification (Springer-Verlag, N.Y. , 1982), which is incorporated herein by reference in its entirety for all purposes) .
  • Substantially pure immunoglobulins of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity most preferred, for pharmaceutical uses.
  • polypeptides may then be used therapeutically (including extracorporeally) or in developing and performing assay procedures, immunofluorescent stainings, and the like.
  • therapeutically including extracorporeally
  • immunofluorescent stainings and the like.
  • humanized immunoglobulins are produced which bind to L-selectin with a binding affinity of at least 1 x 10 7 M "1 in standard binding conditions (e . g. , phosphate-buffered saline with 2 percent fetal bovine serum at 25°C) ; one example of such humanized immunoglobulins is the humanized DREG-200 antibody comprising the amino acid sequences shown in Figure 2.
  • Humanized DREG-200 antibody is sometimes referred to as "hu DREG-200.
  • Humanized immunoglobulins comprising the CDRs from mouse DREG-55 or from mouse DREG-56 also can bind to L- selectin with an affinity of at least 1 x 10 7 M "1 .
  • the humanized antibodies of the invention preferably bind, in standard binding conditions, to human L-selectin with an affinity of at least 1 x 10 8 M" 1 , more preferably with an affinity of at least l x 10 9 M" 1 , and advantageously with an affinity of at least 1 x 10 10 M" 1 or stronger.
  • the binding affinity of a humanized immunoglobulin is within a factor of three of the mouse immunoglobulin from which it was derived.
  • the affinity of the mouse DREG-200 antibody is about 10 8 M "1 .
  • computers programmed to display three dimensional images of antibodies on a monitor are provided.
  • a Silicon Graphics IRIS 4D workstation running under the UNIX operating system and using the molecular modelling package QUANTA (Polygen Corp. USA) is suitable.
  • Computers are useful for generating variants of humanized antibodies.
  • the antibodies of the invention already provide satisfactory binding affinity. However, it is likely that antibodies with even stronger binding affinity could be identified by further variation of certain amino acid residues.
  • the three dimensional image will also identify many noncritical amino acids, which could be the subject of conservative substitutions without appreciable affecting the binding affinity of the antibody. Collectively even conservative substitutions can have a significant effect on the properties of an immunoglobulin. However, it is likely many individual conservative substitutions will not significantly impair the properties of the immunoglobulins.
  • human antibodies against L-selectin are provided. These antibodies are produced by a variety of techniques described below. Some human antibodies are selected by competitive binding experiments, or otherwise, to have the same epitope specificity as a particular mouse antibody, such as mouse DREG-200 or a humanized version thereof. Such antibodies are particularly likely to share the useful therapeutic properties demonstrated for humanized DREG-200.
  • Antibodies having the required epitope specificity can also be identified by screening for the capacity to block neutrophil-endothelial cell interaction.
  • a simple visual assay for detecting such interaction has been described by Kishimoto et al. (1991) , supra . Briefly, monolayers of human umbilical vein cells are stimulated with IL-1. Neutrophils, with or without pretreatment with the antibody under test, are added to the monolayer under defined conditions, and the number of adhering neutrophils is determined microscopically. In one method, the neutrophils are obtained from human leukocyte adhesion deficient patients. See Anderson et al., Ann . Rev. Med. 38:175 (1987). The neutrophils frpm such patients lack integrin receptors, whose binding to neutrophils might obscure the effects of blocking L-selectin binding. a. Trioma Methodology
  • a mouse myeloma line is fused with a human B- lymphocyte to obtain a non-antibody-producing xenogeneic hybrid cell, such- as the SPAZ-4 cell line described by Oestberg, ⁇ upra .
  • the xenogeneic cell is then fused with an immunized human B-lymphocyte to obtain an antibody-producing trioma cell line.
  • Triomas have been found to produce antibody more stably than ordinary hybridomas made from human cells.
  • the immunized B-lymphocytes are obtained from the blood, spleen, lymph nodes or bone marrow of a human donor.
  • B-lymphocytes are usually immunized in vitro with an L-selectin polypeptide, an antigenic fragment thereof or a cell bearing either of these. If antibodies against a specific antigen or epitope are desired, it is preferable to use that antigen or epitope thereof for in vitro immunization.
  • B-lymphocytes are typically exposed to antigen for a period of 7-14 days in a media such as RPMI- 1640 (see Engleman, ⁇ upra) supplemented with 10% human plasma.
  • the immunized B-lymphocytes are fused to a xenogeneic hybrid cell such as SPAZ-4 by well known methods.
  • the cells are treated with 40-50% polyethylene glycol of MW 1000-4000, at about 37 degrees, for about 5-10 min.
  • Cells are separated from the fusion mixture and propagated in media selective for the desired hybrids (e . g . , HAT or AH) .
  • Clones secreting antibodies having the required binding specificity are identified by assaying the trioma culture medium for the ability to bind to L-selectin or a fragment thereof.
  • Triomas producing human antibodies having the desired specificity are subcloned by the limiting dilution technique and grown in vitro in culture medium. The trioma cell lines obtained are then tested for the ability to bind L-selectin or a fragment thereof.
  • triomas are genetically stable they do not produce antibodies at very high levels. Expression levels can be increased by cloning antibody genes from the trioma into one or more expression vectors, and transforming the vector into a cell line such as the cell lines discussed ⁇ upra for expression of recombinant or humanized immunoglobulins.
  • Transgenic Non-Human Mammals Human antibodies against L-selectin can also be produced from non-human transgenic mammals having transgenes encoding at least ' a segment of the human immunoglobulin locus. Usually, the endogenous immunoglobulin locus of such transgenic mammals is functionally inactivated. Preferably, the segment of the human immunoglobulin locus includes unrearranged sequences of heavy and light chain components.
  • transgenic mammals resulting from this process are capable of functionally rearranging the immunoglobulin component sequences, and expressing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes, without expressing endogenous immunoglobulin genes.
  • the production and properties of mammals having these properties are described in detail by, e.g., Lonberg et al. , W093/12227 (1993); Kucherlapati, WO 91/10741 (1991) (each of which is incorporated by reference in its entirety for all purposes) .
  • Anti-L-selectin antibodies are obtained by immunizing a transgenic nonhuman mammal, such as described by Lonberg or Kucherlapati, supra , with L-selectin or a fragment thereof. Monoclonal antibodies are prepared by, e . g . , fusing B-cells from such mammals to suitable myeloma cell lines using conventional Kohler- Milstein technology. c. Phage Display Methods
  • a further approach for obtaining human anti-L- selectin antibodies is to screen a DNA library from human B cells according to the general protocol outlined by Huse et al.. Science 246:1275-1281 (1989). Antibodies binding to L- selectin or a fragment thereof are selected. Sequences encoding such antibodies (or a binding fragments) are then cloned and amplified. The protocol described by Huse is rendered more efficient in combination with phage-display technology. See, e.g., Dower et al., WO 91/17271 and
  • McCafferty et al. WO 92/01047 (each of which is incorporated by reference in its entirety for all purposes) .
  • libraries of phage are produced in which members display different antibodies on their outersurfaces.
  • Antibodies are usually displayed as Fv or Fab fragments.
  • Phage displaying antibodies with a desired specificity are selected by affinity enrichment to an L-selectin polypeptide or fragment thereof.
  • human antibodies having the binding specificity of a selected murine antibody can be produced. See Winter, WO 92/20791.
  • either the heavy or light chain variable region of the selected murine antibody e . g. , mouse DREG-200
  • a phage library is constructed in which members displays the same light chain variable region (i . e . , the murine starting material) and a different heavy chain variable region.
  • the heavy chain variable regions are obtained from a library of rearranged human heavy chain variable regions.
  • a phage showing strong specific binding for L-selectin (e.g., at least 10 8 and preferably at least 10 9 M "1 ) is selected.
  • the human heavy chain, variable region from this phage then serves as a starting material for constructing a further phage library.
  • each phage displays the same heavy chain variable region (i . e . , the region identified from the first display library) and a different light chain variable region.
  • the light chain variable regions are obtained from a library of rearranged human variable light chain regions.
  • phage showing strong specific binding for L-selectin are selected.
  • These phage display the variable regions of completely human anti-L-selectin antibodies. These antibodies usually have the same or similar epitope specificity as the murine starting material (e . g. , mouse DREG-200) .
  • the antibodies of the present invention will typically find use in the treatment of disease conditions with an inflammatory component, especially those which are mediated by neutrophils or T cells.
  • a preferred application is the therapeutic and prophylactic treatment of ischemia- reperfusion injury caused by myocardial infarction, cerebral ischemic event (e.g., stroke), renal, hepatic or splenal infarction, brain surgery, shock, cardiac surgery (e . g. , coronary artery bypass) , elective angioplasty, and the like.
  • Other preferred applications are the treatment of sepsis, adult respiratory distress syndrome, and multiple organ failure.
  • the antibodies will find use in treating injury due to trauma, burns, frostbite or damage to the spinal cord.
  • autoimmune diseases including by way of example and not limitation, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type I diabetes and uveitis, in treating inflammatory diseases of the skin such as psoriasis, and in treating meningitis and encephalitis.
  • Other typical applications are the prevention and treatment of organ transplant rejection and graft-versus-host disease.
  • immunoglobulin of the present invention may also be used in combination with other antibodies, particularly humanized or human antibodies reactive with different adhesion molecules.
  • suitable immunoglobulins include those specific for CDlla, CDllb, CD18, E-selectin, ⁇ P-selectin and ICAM-1.
  • suitable antibodies are those specific for lymphokines, such as IL-1, IL-2 and IFN- , and their receptors.
  • the antibodies of the invention can also be used as separately administered compositions given in conjunction with che otherapeutic agents.
  • the agents may include non-steroidal anti-inflammatory drugs and corticosteroids, but numerous additional agents (e . g. , cyclosporin) well-known to those skilled in the art of medicine may also be utilized.
  • additional agents e . g. , cyclosporin
  • the im unoglobins of the present invention will typically be used in combination with drugs currently used by those skilled in the art to treat particular diseases.
  • anti-L- selectin antibodies are used in combination with thrombolytic agents.
  • patients with acute myocardial infarction are often treated by opening the occluded coronary artery.
  • Reopening of the obstructed coronary artery can be achieved by administration of thrombolytic agents which lyse the clot causing the obstruction, and which, thereby, restore coronary blood flow.
  • Reperfusion of the vessel can also be achieved by acute percutaneous transluminal coronary angioplasty (PTCA) by means of balloon dilation of the obstructed and narrowed segment of the coronary artery.
  • PTCA acute percutaneous transluminal coronary angioplasty
  • restoration of coronary blood flow leads to ischemia-reperfusion injury in prior methods.
  • ischemia-reperfusion injury is reduced or prevented by combination of a thrombolytic agent or of PTCA with humanized or human anti-L-selectin antibodies.
  • Antibodies are usually administered prophylactically before, or at the same time as, administration of thrombolytic agents or initiation of PTCA. Further doses of antibody are then often administered during and after thrombolytic or angioplastic treatment.
  • the interval between prophylactic administration of the antibodies and initiation of thrombolytic or angioplastic treatment is usually 5 - 30 mins, preferably 5 - 20 min, and most preferably 5 - 10 min.
  • the antibodies are administered parentally, preferably by intravenous injection, in doses of 0.01 - 10 mg/kg body weight, preferably of 0.14 - 5 mg/kg and most preferably of 0.3 - 3 mg/kg.
  • the antibodies can be given as an intravenous bolus injection, e . g. , over 1 - 5 min., as repeated injections of smaller doses, or as an intravenous infusion.
  • the bolus injection is especially useful for the prophylactic dose or in an emergency.
  • Further doses of antibodies can be repeated (e . g. , every 4 - 6 h) during and after thrombolytic or angioplastic treatment of acute myocardial infarction at the same proportions as described above to achieve optimal plasma levels of the antibody.
  • Thrombolytic agents are drugs having the capacity, directly or indirectly, to stimulate dissolution of thrombi in vivo .
  • Thrombolytic agents include tissue plas inogen activator (see EP-B 0 093 619) , activase, alteplase, duteplase, silteplase, streptokinase, anistreplase, urokinase, heparin, warfarin and coumarin.
  • Additional thrombolytic agents include saruplase and vampire bat plasminogen activator. See Harris, Protein Engineering 6:449-458 (1987) ; ' PCT/EP 90/00194; US Patent 4,970,159).
  • Thrombolytic agents are administered to a patient in an amount sufficient to partially disperse, or prevent the formation of, thrombi and their complications.
  • An amount adequate to accomplish this is defined as a "therapeutically effective dose” or “efficacious dose.” Amounts effective for this use will depend upon the severity of the condition, the general state of the patient, the route of administration and combination with other drugs.
  • therapeutically effective doses of thrombolytic agents and administration regimens for such agents are those approved by the FDA, for independent uses of thrombolytic agents, e.g., 100 mg of alteplase or 1.5 million IU of streptokinase.
  • a preferred pharmaceutical composition of the present invention comprises the use of the subject immunoglobulins in immunotoxins to kill L-selectin expressing cells.
  • Iitununotoxins are characterized by two components and are particularly useful for killing selected cells in vitro or in vivo .
  • One component is a cytotoxic agent which is usually fatal to a cell when attached or absorbed.
  • the second component known as the "delivery vehicle,” provides a means for delivering the toxic agent to a particular cell type, such as cells expressing a L-selectin epitope.
  • the two components are commonly chemically bonded together by any of a variety of well-known chemical procedures.
  • the linkage may be by way of heterobifunctional cross-linkers, e.g., SPDP, carbodiimide, glutaraldehyde, or the like.
  • heterobifunctional cross-linkers e.g., SPDP, carbodiimide, glutaraldehyde, or the like.
  • Production of various immunotoxins is well-known with the art, and can be found, for example in "Monoclonal Antibody-Toxin Conjugates: Aiming the Magic Bullet," Thorpe et al., Monoclonal Antibodie ⁇ in Clinical Medicine , Academic Press, pp. 168-190 (1982) , which is incorporated herein by reference in its entirety for all purposes.
  • the components may also be linked genetically (see Chaudhary et al., Nature 339:394 (1989), incorporated herein by reference in its entirety for all purposes) .
  • Cytotoxic agents are suitable for use in immunotoxins.
  • Cytotoxic agents can include radionuclides, such as Iodine-131 or other isotopes of iodine, Yttrium-90, Rhenium-188, and Bismuth-212 or other alpha emitters; a number of chemotherapeutic drugs, such as vindesine, methotrexate, adriamycin, and cisplatin; and cytotoxic proteins such as ribosomal inhibiting proteins like pokeweed antiviral protein, Pseudomonas exotoxin A, ricin, diphtheria toxin, ricin A chain, etc., or an agent active at the cell surface, such as the phospholipase enzymes (e .g.
  • the delivery component of the immunotoxin will include the immunoglobulins of the present invention. Intact immunoglobulins or their binding fragments, such as Fab or Fv, are preferably used.
  • the antibodies in the immunotoxins will be of the human IgM or IgG isotype, but other mammalian constant regions may be utilized as desired.
  • the antibodies and pharmaceutical compositions thereof of this invention are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly or intravenously.
  • the antibodies of the invention may also be administered, typically for local application, by gavage or lavage, intraperitoneal injection, ophthalmic ointment, topical ointment, intracranial injection (typically into a brain ventricle) , intrapericardiac injection, or intrabursal injection.
  • the compositions for parenteral administration will commonly comprise a solution of the immunoglobulin or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier.
  • an aqueous carriers can be used, e .g. , water, buffered water, phosphate buffered saline (PBS), 0.4% saline, 0.3% glycine, human albumin solution and the like.
  • compositions may be sterilized by conventional, well-known sterilization techniques.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride and sodium lactate.
  • concentration of antibody in these formulations can vary widely, i . e . , from less than about 0.005%, usually at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
  • a typical pharmaceutical composition for injection could be made up to contain 1 ml sterile buffered water, and 1-70 mg of immunoglobulin.
  • a typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 mg of antibody.
  • Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, Remington ' Pharmaceutical Science (15th ed. , Mack Publishing Company, Easton, Pennsylvania, 1980) , which is incorporated herein by reference in its entirety for all purposes.
  • Compositions suitable for lavage or other routes will be selected according to the particular use intended.
  • Some pharmaceutical compositions comprise both anti-L-selectin antibodies and thrombolytic agents.
  • the antibodies of this invention can be frozen or lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immune globulins and art-known lyophilization and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilization and reconstitution can lead to varying degrees of antibody activity loss (e.g., with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be ad ⁇ justed to compensate.
  • compositions containing the present antibodies or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments.
  • compositions are administered to a patient already suffering from an inflammatory disease, in an amount sufficient to cure or at least partially arrest the disease and its complica ⁇ tions.
  • An amount adequate to accomplish this is defined as a "therapeutically effective dose.”
  • Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's own immune system, but generally range from about 1 to about 200 mg of antibody per dose, with dosages of from 5 to 70 mg per patient being more commonly used.
  • Dosing schedules will vary with the disease state and status of the patient, and will typically range from a single bolus dosage or continuous infusion to multiple administrations per day (e .g.
  • compositions containing the present antibodies or a cocktail thereof are administered to a patient not already suffering from a particular disease to enhance the patient's resistance.
  • prophylactically effective dose Such an amount is defined to be a “prophylactically effective dose.”
  • the precise amounts again depend upon the patient's state of health and general level of immunity, but generally range from 1 to 70 mg per dose.
  • Preferred prophylactic uses are for the prevention of adult respiratory distress syndrome in patients already suffering from sepsis or trauma; prevention of organ transplant rejection; and prevention of reperfusion injury in patients suffering from ischemia. In seriously ill patients, dosages of about 50 to 150 mg of humanized or human immunoglobulin per administration are frequently used, and larger dosages may be indicated.
  • compositions can be carried out with dose levels and pattern being selected by the treating physician.
  • pharmaceutical formulations should provide a quantity of the antibody(ies) of this invention sufficient to effectively treat the patient.
  • Antibodies of the present invention can further find a wide variety of utilities in vitro .
  • the antibodies can be utilized for detection of L- selectin antigens, for isolating specific leukocytes, or the like.
  • a humanized DREG- 200 immunoglobulin can be immobilized and contacted with blood extravasated from a patient to remove blood cells bearing L-selectin antigens, and the remaining blood, depleted of L-selectin-bearing cells, may be reintroduced into the patient. Any residual humanized antibody present in the depleted blood reintroduced into the patient (e.g., as a consequence of detachment from the immobilization support) would have reduced or negligible antigenicity as compared to a murine antibody.
  • the antibodies may either be labeled or unlabeled.
  • Unlabeled antibodies can be used in combination with other labeled antibodies (second antibodies) that are reactive with the humanized or human antibody, such as antibodies specific for human immunoglobulin constant regions.
  • second antibodies labeled antibodies
  • the antibodies can be directly labeled.
  • labels may be employed, such as radionuclides, fluors, enzymes, enzyme substrates, enzyme co- factors, enzyme inhibitors, ligands (particularly haptens) , etc. Numerous types of immunoassays are available and are well known to those skilled in the art.
  • gamma-1 specific and two kappa specific clones were sequenced.
  • the gamma-1 clones and the kappa clones are respectively identical in sequence.
  • the cDNA variable domain sequences and the deduced amino acid sequences are shown in Fig. 1.
  • the heavy chain and light chain from the same human antibody are chosen to provide the framework sequences, so as to reduce the possibility of incompatibility in the assembling of the two chains.
  • sequence homology search against the NBRF protein sequence database performed with the MicroGenie Sequence Analysis Software (Beckman) ) , the antibody Eu was chosen to provide the framework sequences for humanization of mouse DREG-200.
  • the computer program ENCAD (Levitt, J. Mol . Biol . 168:595 (1983), which is incorporated herein by reference in its entirety for all purposes) was used to construct a model of the mouse DREG-200 variable region.
  • the model was used to determine the amino acids in the mouse DREG-200 framework that were close enough to the CDRs to potentially v interact with them (category 4 below) .
  • DREG-200 amino acid was different but also unusual. Then an amino acid typical for human antibodies at that position was used. The amino acids in each category are shown in Table 1. Some amino acids may be in more than one category. The final sequences of the humanized DREG-200 light and heavy chain variable domains are shown in Fig. 2, compared with the murine DREG-200 sequences.
  • nucleotide sequences were selected that encode the protein sequences of the humanized heavy and light chains, including signal peptides, generally utilizing codons found i the mouse sequence. Several degenerate codons were changed to create restriction sites or to remove undesirable ones.
  • the nucleotide sequences of the genes also included splice donor signals and an Xbal site at each end. The nucleotide sequences and encoded humanized light and heavy chain variable domains are shown in Fig. 3. Each gene was constructed from four overlapping synthetic oligonucleotides, as described (see Co et al., J. Immunol . 148:1149 (1992), and commonly assigned U.S.S.N.
  • the heavy chain and light chain plasmids were transfected into Sp2/0 mouse myeloma cells by electroporation and cells were selected for gpt expression. Clones were screened by assaying human antibody production in the culture supernatant by ELISA, and antibody was purified from the best- producing clones. Humanized DREG-200 IgGl antibody was then purified by passing tissue culture supernatant over a column of staphylococcal protein A-Sepharose CL-4B (Pharmacia) . The bound antibody was eluted with 0.2 M Glycine-HCl, pH3.0 and neutralized with 1 M Tris PH8.0.
  • the buffer was exchanged into PBS by passing over a PD10 column (Pharmacia) , or by dialysis.
  • the transfected clones may be cultured in increasin concentrations of methotrexate.
  • the humanized DREG-200 heavy chain variable region gene was then cloned into the Xba site of pVg4-dhfr. This heavy chain plasmid was then transfected together with the above light chain plasmid into Sp2/0 cells, clones selected, and humanized DREG-200 IgG4 antibody purified as described above for the IgGl antibody.
  • Example 3 Properties of Humanized Antibodies.
  • the affinity of the humanized DREG-200 antibodies for L-selectin were determined by competition with the radio- iodinated mouse DREG-200 antibody (Fig. 4) .
  • the binding affinities were calculated according to the methods of Berzofsky (J.A. Berzofsky and I.J. Berkower, in Fundamental Immunology (ed. W.E. Paul), Raven Press (New York), 595 (1984), which is incorporated herein by reference in its entirety for all purposes) .
  • the humanized DREG-200 antibodie had an affinity within about 2-fold of the mouse DREG-200 antibody. A similar result will be found when the affinity for L-selectin on. human neutrophils is measured.
  • the ability of the mouse and humanized DREG-200 antibodies to block the adhesion of human neutrophils to endothelial cells was determined using a modification of the assay method of Hall ann et al., Biochem . Biophys . Res . Comm . 174:236 (1991). Specifically, human umbilical cord endothelial cells (HUVEC; from Clonetics, San Diego) were grown to confluence in EGM medium (Clonetics) in Lab-Tek 8- chamber slides (Nunc, Naperville, IL) . The HUVEC cells were stimulated with 20 ng/ml IL-1/3 (R&D Systems, Minneapolis, MN) for 4 hr before use.
  • HUVEC human umbilical cord endothelial cells
  • Neutrophils were isolated by density gradient centrifugation from buffy coats that had been clear of erythrocytes by dextran sedimentation, and then adjusted 10 7 per ml.
  • the neutrophils (100 ⁇ l) were pre-incubated for 20 minutes on ice with varying concentrations of antibody (i 100 ⁇ l RPMI) .
  • the HUVEC slides were washed free of IL-13 an placed on a rotary shaker (100 rpm) at 4°C.
  • the untreated o antibody treated neutrophils were added to the chambers, and the slide was incubated at 4°C on the shaker for 30 min.
  • Th slides were then washed by dipping ten times into a beaker o RPMI, fixed in 1% glutaraldehyde in RPMI, and allowed to air dry. Neutrophil adherence was quantified by counting the neutrophils attached to a defined area of the endothelial ce monolayer with a microscope. As shown in Fig. 5, the humanized IgGl and mouse DREG-200 antibodies both effectivel blocked the binding of neutrophils to the HUVEC, while an irrelevant control antibody did not. The humanized DREG-200 IgG4 antibody will similarly block binding of neutrophils to endothelial cells-.
  • Example 4 Effect of hu DREG-200 on Myocardial Injury Following Reperfusion.
  • a polyethylene catheter was inserted through the left femoral artery and positioned in the abdominal aorta for the measurement of mean arterial blood pressure (MABP) via a pressure transducer (Cobe Instruments, Lakewood, CO) .
  • MABP mean arterial blood pressure
  • CO pressure transducer
  • the anterior pericardium was incised, and a 3-0 silk suture was placed around the left anterior descending (LAD) coronary artery 8 to 10 mm from its origin.
  • a high-fidelity catheter tip pressure transducer Model MPC 500, with transducer control unit - Model TCB 500, Millar
  • the ECG, MABP, LVP and dP/dt were continuously monitored on a Hewlett-Packard 78304 unit (Hewlett-Packard, Palo Alto, CA) and recorded on a Goul oscillographic recorder (Gould Inc., Cleveland, OH) every 20 min.
  • the pressure-rate index (PRI) an approximation of myocardial oxygen demand, was calculated as the product of MABP and HR divided by 1000. After completing all surgical procedures, the cats were allowed to stabilize for 30 minutes, at which time baseline readings of ECG, MABP, LVP and dP/dt were recorded.
  • MI Myocardial ischemia
  • the ligature around the LAD was again tightened. 20 ml of 0.5% Evans blue was rapidly injected into the left ventricle to stain the area of myocardium which was perfused by the patent coronary arteries. The area-at-risk was determined by negative staining.
  • the heart was rapidly excised and placed in warmed, oxygenated K- solution.
  • the left circumflex (LCX) and the LAD coronary arteries were isolated and removed for subsequent study of coronary ring vasoactivity and PMN adherence. The right ventricle, great vessels, and fat tissue were carefully removed, and the left ventricle was sliced parallel to the atrioventricular groove in 3 mm thick sections.
  • the unstaine portion of the myocardium i.e., the total area-at-risk or ischemic area
  • the area-at-risk was sectioned into small cubes and incubated in 0.1% nitroblue tetrazolium in phosphat solution at pH 7.4 and 37°C for 15 min.
  • the tetrazolium dye forms a blue formazan complex in the presence of myocardial cells containing active dehydrogenases and their cofactors.
  • the three portions of the myocardium i.e., non-ischemic, ischemic non-necrotic, and ischemic necrotic tissue) were subsequently weighed. Results were expressed as necrotic cardiac tissue area as a percentage of either the area-at-risk or of total left ventricular mass.
  • DREG-200 is further illustrated from measurements of plasma creatine kinase activity, a biochemical marker of myocardial injury.
  • Arterial blood samples (2 ml) were drawn immediately before ligation and hourly thereafter. The blood was collected in polyethylene tubes containing 200 IU of heparin sodium. Samples were centrifuged at 2000 x g and 4°C for 20 min and the plasma was decanted for biochemical analysis. Plasma protein concentration was assayed using the biuret method of Gornall et al., J. Biol . Chem . 177:751-766 (1949). Plasma creatine kinase (CK) activity was measured using the method of Rosalki, J. Lab . Clin Med. 69:696-705 (1967), and expressed as IU/ ⁇ g protein.
  • hu DREG-200 IgG4 isotype
  • dP/dt max a index of myocardial contractility.
  • Data were obtained from a catheter tip manometer inserted in the left ventricular cavity.
  • the three groups of cats discussed in the previous example all showed comparable initial values for these cardia variables.
  • dP/dt max decreased upon occlusion of the LAD to about 65%.
  • contractility did not significantly recover.
  • the immunoglobulins of the present invention offer numerous advantages over other L-selectin specific antibodies.
  • the present intmunoglobulins can be more economically produced and contain substantially less foreign amino acid sequences. This reduce likelihood of antigenicity after injection into a human patient represents a significant therapeutic improvement.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Des immunoglobulines humanisées, réagissant spécifiquement avec L-sélectine sont préparées au moyen de techniques de recombinaison d'ADN et sont utilisées pour traiter, notamment, des troubles inflammatoires.
EP94903357A 1992-12-01 1993-11-30 Anticorps humanises reagissant avec l-selectine. Withdrawn EP0671951A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98394692A 1992-12-01 1992-12-01
US983946 1992-12-01
PCT/US1993/011612 WO1994012215A1 (fr) 1992-12-01 1993-11-30 Anticorps humanises reagissant avec l-selectine

Publications (2)

Publication Number Publication Date
EP0671951A1 true EP0671951A1 (fr) 1995-09-20
EP0671951A4 EP0671951A4 (fr) 1997-05-21

Family

ID=25530200

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94903357A Withdrawn EP0671951A4 (fr) 1992-12-01 1993-11-30 Anticorps humanises reagissant avec l-selectine.

Country Status (12)

Country Link
EP (1) EP0671951A4 (fr)
JP (1) JPH08503617A (fr)
KR (1) KR100371784B1 (fr)
AU (1) AU689090B2 (fr)
CA (1) CA2149025A1 (fr)
CZ (1) CZ140195A3 (fr)
FI (1) FI952658A0 (fr)
HU (1) HUT71790A (fr)
NO (1) NO952160L (fr)
PL (1) PL309249A1 (fr)
RU (1) RU2151612C1 (fr)
WO (1) WO1994012215A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
WO1996040942A1 (fr) * 1995-06-07 1996-12-19 Cytel Corporation Anticorps humanises anti-e-selectine
AU746888B2 (en) * 1995-08-17 2002-05-02 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
ATE265861T1 (de) * 1995-08-17 2004-05-15 Protein Design Labs Inc Antikörper gegen l-selectin zur vorbeugung von multiplem organversagen und akuter organschädigung
DE69737562T2 (de) * 1996-09-27 2007-12-27 The Trustees Of Columbia University In The City Of New York Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
WO1999043353A2 (fr) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Therapie combinee par anti-selectine et immunodepresseur
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
EP4342995A3 (fr) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Procédés de régulation de la pharmacocinétique sanguine d'anticorps
RU2511406C2 (ru) 2006-06-08 2014-04-10 Чугаи Сейяку Кабусики Кайся Профилактическое или лекарственное средство для воспалительного заболевания
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
PE20090711A1 (es) 2007-09-26 2009-07-15 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo mutante
ES2585480T3 (es) 2007-12-05 2016-10-06 Chugai Seiyaku Kabushiki Kaisha Anticuerpo anti-NR10 y uso del mismo
RU2596397C2 (ru) 2007-12-05 2016-09-10 Чугаи Сейяку Кабусики Кайся Терапевтическое средство от зуда
KR102051275B1 (ko) 2008-04-11 2019-12-04 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
AU2011286185B2 (en) * 2010-07-26 2014-08-14 Trianni, Inc. Transgenic animals and methods of use
EP2601298B1 (fr) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Souris produisant des protéines d'attachement comprenant des domains vl
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
WO2012088265A1 (fr) * 2010-12-21 2012-06-28 Selexys Pharmaceuticals Corporation Anticorps anti-p-sélectine et leurs procédés d'utilisation et d'identification
RS64280B1 (sr) 2011-02-25 2023-07-31 Regeneron Pharma Adam6 miševi
DK3865581T3 (da) 2011-08-05 2024-10-21 Regeneron Pharma Humaniserede, universelle letkædemus
ES2720186T3 (es) 2011-12-20 2019-07-18 Regeneron Pharma Ratones con cadenas ligeras humanizadas
AU2013204582B2 (en) 2012-06-12 2016-01-14 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
CA2942697A1 (fr) 2014-03-21 2015-09-24 Lynn Macdonald Animaux non humains qui produisent des proteines de liaison monodomaine
CA2979702A1 (fr) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Animaux non humains qui selectionnent des regions variables de chaines legeres qui se lient a l'antigene
MX2017013141A (es) 2015-04-14 2018-02-21 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
CN114728064A (zh) 2019-11-20 2022-07-08 中外制药株式会社 含抗体制剂
WO2024194605A1 (fr) 2023-03-17 2024-09-26 Quell Therapeutics Limited Thérapie treg

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011018A1 (fr) * 1990-12-19 1992-07-09 Protein Design Labs, Inc. Immunoglobulines humanisees ameliorees

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011018A1 (fr) * 1990-12-19 1992-07-09 Protein Design Labs, Inc. Immunoglobulines humanisees ameliorees

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Etzioni A. et al: (1992) New Engl. J. Med. 327:1789-1792 *
Fischer A.; Lisowska-Grospierre B.: (1998) Immunodef. Rev. 1:39-54 *
Kansas G.S.: (1996) Blood 88: 3259-3287 *
See also references of WO9412215A1 *
Simpson P.J. et al: (1988) J. Clin. Invest. 81:624-629 *

Also Published As

Publication number Publication date
AU5732794A (en) 1994-06-22
FI952658A (fi) 1995-05-31
CA2149025A1 (fr) 1994-06-09
NO952160L (no) 1995-07-31
CZ140195A3 (en) 1996-06-12
PL309249A1 (en) 1995-10-02
KR100371784B1 (ko) 2003-07-22
WO1994012215A1 (fr) 1994-06-09
AU689090B2 (en) 1998-03-26
HU9501564D0 (en) 1995-07-28
FI952658A0 (fi) 1995-05-31
NO952160D0 (no) 1995-05-31
JPH08503617A (ja) 1996-04-23
EP0671951A4 (fr) 1997-05-21
HUT71790A (en) 1996-02-28
RU2151612C1 (ru) 2000-06-27

Similar Documents

Publication Publication Date Title
AU689090B2 (en) Humanized antibodies reactive with L-selectin
US6210671B1 (en) Humanized antibodies reactive with L-selectin
US6210670B1 (en) Cross-reacting monoclonal antibodies specific for E-selectin and P-selectin
EP0566647B1 (fr) Immunoglobulines humanisees ameliorees
CA2328851C (fr) Immunoglobulines humaines; leurs productions et utilisations
EP0753065B1 (fr) Anticorps contre la selectine e
AU3544589A (en) Il-2 receptor-specific chimeric antibodies
WO1994012214A1 (fr) Anticorps humanises reagissant avec la cd-18
US20030064068A1 (en) Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody
EP0606391B1 (fr) Inhibition du retrecissement vasculaire par l'utilisation d'anticorps anti-padgem
WO1995015181A1 (fr) Therapie de reperfusin comprenant l'utilisation d'anticorps diriges contre la l-selectine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950630

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTEIN DESIGN LABS, INC.

17Q First examination report despatched

Effective date: 20000407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041126